Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Tomohiko Kono"'
Autor:
Toshiya Inaba, Hirotaka Matsui, Mayu Onishi, Shoichi Takahashi, Eiji Iwao, C. Nelson Hayes, Ichimaro Yamada, Tomohiko Kono, Naohiro Kamiya, Akinori Kanai, Kazuaki Chayama, Michio Imamura, Katsutoshi Yoshizato, Hidenori Ochi, Nobuhiko Hiraga, Hiromi Abe, Chise Tateno, Masataka Tsuge, Shinji Tanaka
Publikováno v:
Hepatology. 54:781-788
Telaprevir is a potent inhibitor of hepatitis C virus (HCV) NS3-4A protease. However, the emergence of drug-resistant strains during therapy is a serious problem, and the susceptibility of resistant strains to interferon (IFN), as well as the details
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5a7a809085bff011ffd9d7fda7db83ac
https://doi.org/10.1002/hep.24460
https://doi.org/10.1002/hep.24460
Autor:
Hiromi Abe, C. Nelson Hayes, Ichimaro Yamada, Eiji Iwao, Tomohiko Kono, Naohiro Kamiya, Kazuaki Chayama, Hidenori Ochi, Tomokazu Kawaoka, Masataka Tsuge, Daizaburo Hirata, Nobuhiko Hiraga, Chise Tateno, Shoichi Takahashi, Fukiko Mitsui, Eiji Ohara, Mayu Onishi, Katsutoshi Yoshizato, Shinji Tanaka, Michio Imamura
Publikováno v:
Journal of hepatology. 54(5)
Background & Aims The current treatment regimen for chronic hepatitis C virus (HCV) infection is peg-interferon plus ribavirin combination therapy. The majority of developing therapeutic strategies also contain peg-interferon with or without ribaviri
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::936f328e2a4bc07a337f8671f7ff94c7
https://pubmed.ncbi.nlm.nih.gov/21145816
https://pubmed.ncbi.nlm.nih.gov/21145816